Necrobiosis Lipoidica (Investigational Adjunct)

Investigational adjunct for stable non-ulcerated necrobiosis lipoidica; topical and intralesional corticosteroids, topical calcineurin inhibitors, glycemic optimization in diabetes, and (refractory) TNF inhibitors or fumaric acid esters remain evidence-based.

Tier C — InvestigationalИсследовательское применениеLast updated: 2026-05-26 · Reviewed by ASH Editorial Board

Краткая информация для пациента

Есть ли FDA-допуск для этого показания?: Not FDA-cleared for necrobiosis lipoidica. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
Какие доказательства существуют?: Tier C (investigational). No controlled trials with active comparators showing leech benefit. Evidence-based first-line management of necrobiosis lipoidica is high-potency topical or intralesional corticosteroid for active borders, optimization of glucose control if diabetic (though this often does not change the skin disease), tight wound care if ulceration occurs, topical tacrolimus, pentoxifylline, and for refractory disease systemic options including biologic anti-TNF therapy or PUVA.
Основные риски: Bleeding from each bite site for 6 to 10 hours after the leech detaches
Iron-deficiency anemia from cumulative blood loss across multiple sessions
Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
Permanent Y-shaped bite-mark scars or hyperpigmentation at attachment sites
Local pain, bruising, swelling, or itching for 1 to 3 days after each session
Ulceration of fragile necrobiotic skin — up to 30 percent of NL lesions ulcerate spontaneously and may not heal
Bleeding into atrophic tissue that does not seal normally
Risk of chronic non-healing bite ulcers
Infection of ulcerated NL is hard to treat
Кому не следует это рассматривать: Patients with already-ulcerated NL (any new wound may not heal)
Patients with severely atrophic, telangiectatic lesions
Patients without optimization of topical corticosteroid trial
Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran, heparin, or daily aspirin used for medical reasons
People with hemophilia or any other inherited bleeding disorder
Patients with severe anemia (hemoglobin under 10 g/dL)
People with an active infection at the planned application site
О чём спросить врача: Has my diagnosis been confirmed by biopsy and other granulomatous diseases ruled out?
Have I had a proper trial of topical and intralesional corticosteroid?
Have pentoxifylline, topical tacrolimus, or biologic therapy been considered?
What is the risk that bite sites in my skin do not heal?
What is the published evidence base for leeches in NL specifically?
What is the wound-care plan if a bite site ulcerates?
Когда срочно обратиться за медицинской помощью: Bleeding from a bite site that soaks through more than one dressing per hour
Bleeding that continues more than 24 hours after the leech detached
Spreading redness, warmth, swelling, pus, or red streaks around any bite site
Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
Non-healing or expanding ulceration in any NL lesion
Sudden change in a lesion (rule out squamous cell carcinoma developing in chronic NL)
Spreading redness, warmth, or pus around any lesion

Что это НЕ означает

It does not mean leech therapy is FDA-cleared for necrobiosis lipoidica — the only FDA clearance is venous congestion in microsurgical reconstruction (K040187, June 2004).
It does not replace topical or intralesional corticosteroid, the standard first-line therapy.
It does not address the underlying granulomatous and microvascular pathology.
It carries a substantial risk of non-healing bite ulcers in this fragile skin.
It does not have controlled-trial evidence in NL.

Перекрёстные ссылки безопасности

Clinical Profile

Category: dermatological
ICD-10: L92.1, E08.620, E09.620, E10.620, E11.620, E13.620
Safety tier: high

Evidence Summary

Necrobiosis lipoidica is a granulomatous dermatosis producing yellow-brown atrophic plaques with telangiectasias, classically on the pretibial surfaces, with strong association to diabetes mellitus (though present in non-diabetics). Lesions may ulcerate, particularly after trauma, and ulceration is the principal morbidity. Evidence-based management: glycemic optimization in diabetes, high-potency topical or intralesional corticosteroids for active inflammatory borders, topical calcineurin inhibitors as steroid-sparing, and (refractory) TNF-alpha inhibitors, fumaric acid esters, or pentoxifylline. No published controlled trials of hirudotherapy exist for necrobiosis lipoidica. Direct lesion placement is high-risk for triggering ulceration; uninvolved-skin placement has been mentioned anecdotally without efficacy data.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)

Contraindications

Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
Hemophilia or other bleeding disorder
Severe anemia (Hb <10 g/dL)
Active bacteremia or sepsis
Known hypersensitivity to leech salivary proteins
Pregnancy (relative — first/third trimester)
Immunocompromised state with severe neutropenia
Placement directly on necrobiosis lipoidica plaque (absolute — triggers ulceration)
Active ulceration of the lesion
Poorly controlled diabetes (HbA1c >8.5 percent)
Diabetic peripheral neuropathy with reduced protective sensation at placement site
Diabetic peripheral arterial disease with ABI <0.6

Related Conditions

Livedo Reticularis

Investigational use for primary livedo reticularis; very limited evidence. Secondary causes (lupus, APLAS) require rheumatology referral.

Lipodermatosclerosis

Investigational use for chronic lipodermatosclerosis; small case series suggest softening of fibrotic gaiter-area skin changes.

Insulin Injection Lipohypertrophy

Investigational use to soften and remodel insulin injection-related lipohypertrophy nodules; very limited evidence.

Androgenic Alopecia

Investigational use for androgenic alopecia; mechanism via local scalp perfusion improvement. Single-arm series only.